Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.
Patients at the centre of rare disease therapy development
Three Posters on New Lynovex Preclinical and Clinical Data
Novabiotics To Present New Data On Their Novel Cystic Fibrosis Drugs At The European Cf Society’S Annual Conference
Novabiotics Presenting New Data At European Cystic Fibrosis Conference
Grant Support For Lynovex